Ataxia telangiectasia (A-T) is a rare autosomal recessive neurologic disorder, characterized by progressive cerebellar degeneration and oculocutaneous telangiectasia. A-T appears to be completely penetrant and is typically diagnosed in early childhood, although the precise clinical phenotype varies from patient to patient. Most cancers in A-T patients are childhood lymphoid leukemias and lymphomas, but there is also a substantial risk of epithelial tumors later in life ( 1 ) . Almost all cases of A-T have been shown to be associated with mutations in the ATM gene, the product of which plays a central role in the recognition and repair of double-strand DNA breaks and in the activation of cell cycle checkpoints ( 2 ) . Most A-T patients are compound heterozygotes; homozygous carriers are uncommon, except in consanguineous families or in the case of a few population-specifi c founder mutations.
It has frequently been suggested that the blood relatives of A-T patients (i.e., obligate or potential heterozygous ATM mutation carriers) have an increased risk of cancer, primarily breast cancer. Clearly, it is important to reliably establish the cancer risks in heterozygous carriers to provide appropriate advice to the relatives of A-T patients. However, the question may also have wider public-health relevance. Some estimates of the frequency of ATM mutation carriers in Western populations are as high as 1% ( 3 , 4 ) , so that a relatively modest increase in breast cancer risk could equate to a substantial population attributable risk.
Studies assessing the risk of breast cancer in heterozygous ATM mutation carriers fall in two broad categories. First, several groups have compared breast cancer incidence and/or mortality in relatives of A-T patients with that in the general population or in married-in family members ( 5 -10 ) . A review of four such studies estimated the breast cancer relative risk (RR) to be 3.9 (95% confi dence interval [CI] = 2.1 to 7.2) ( 11 ) . Subsequent studies have found slightly more modest results, with relative risks between 2.4 and 3.4; most studies report that relative risks are higher among younger women ( 5 , 9 , 11 , 12 ) .
An alternative approach is to compare the frequency of ATM mutations in breast cancer case patients with that in control subjects. Case -control studies have almost uniformly failed to fi nd an increased frequency of pathogenic ATM mutations in case patients, even when restricted to early-onset cancers ( 4 , 13 -16 ) . A review of 10 studies showed that ATM mutations are statistically signifi cantly more frequent in breast cancer case patients selected on the basis of a family history of breast cancer than in unselected case patients ( 17 ) , although other studies have not replicated this result ( 18 ) .
The fi ndings from the family studies and the case -control studies are not necessarily incompatible, given the widths of the confi dence intervals; the sample sizes in many studies are too small to detect a modest increase in risk. Moreover, some studies have suggested that certain missense ATM mutations, notably 7271T>G, may be associated with higher risks of breast cancer ( 14 , 17 , 19 -22 ) , whereas most of the earlier population-based studies used mutation detection techniques that are biased in favor of detecting truncating mutations.
In addition to the potential association between ATM and breast cancer, several studies have reported an increase in the overall risk of cancer in relatives of A-T patients. One review found that the risk of non-breast cancers in carriers was almost double that expected in the general population ( 11 ) . Several cancer sites have been mentioned in this context, but no statistically signifi cant associations with particular cancers have been reported to date ( 6 , 9 , 12 , 23 , 24 ) . If the risks of any other specifi c tumor types are genuinely increased in heterozygous ATM carriers, no study has yet had suffi cient power to demonstrate this.
This study aimed to provide more precise estimates of the risks of cancer in heterozygous ATM mutation carriers by examining the cancer incidence and mortality experienced by the relatives of 169 A-T patients from 139 families living in the UK. This is by far the largest group of A-T families outside the US to have been studied to date and represents the large majority of A-T case patients diagnosed in the UK during the last 20 years. A second aim was to investigate potential differences in cancer risks associated with different types of ATM mutations.
S UBJECTS AND M ETHODS

Data Collection
Families were ascertained on the basis of at least one family member having been given a clinical diagnosis of A-T. The majority of the families (121 families) were ascertained via contact with the A-T Society, a UK support group for people with A-T and their families, or after referral by their pediatric neurologist to the Cancer Research UK Institute for Cancer Studies for diagnosis, genetic testing, and research purposes. In addition, to avoid biasing the cohort towards relatives of living A-T patients, a list of all death certifi cates since 1979 that mentioned A-T was obtained from the Offi ce of National Statistics, leading to the inclusion of a further 18 families. Forty-four of the families were included in a previous study ( 7 ) , but the data used here include a larger number of relatives, 7.5 years of additional follow-up, and information about cancer incidence and mortality.
After we sought permission to contact the parents of each A-T patient from his or her general practitioner, the parent or parents who had agreed to participate in the study were sent a questionnaire requesting basic information about themselves and their children, siblings, parents, and grandparents (i.e., the siblings, aunts, uncles, grandparents, and great-grandparents of the A-T patient). All parents returning questionnaires gave written informed consent. The requested information for each relative comprised name, date and place of birth, vital status, and date of death, where applicable, whether he or she had ever had a cancer, and if so, the type of cancer, age at diagnosis, and place of treatment. Dates of birth were confi rmed from national birth registers, and birth, death, and marriage registers were used to trace relatives in families for which the questionnaire was incomplete. Data were also obtained in this way for families for whom no questionnaire was available and for families ascertained via death certifi cate. An attempt was made to " fl ag " each of the relatives listed above through the National Health Service Central Register (NHSCR). The NHSCR receives notifi cation of all deaths in the UK and all cancer registrations from cancer registries covering the UK, and the study coordinator was informed of these events in study subjects. Individuals were excluded from the study if tracing was not possible. Cancer diagnoses were included in the analysis only if they had been confi rmed by the NHSCR, to allow valid comparison with population-based incidence rates.
Ethical approval was obtained from the South Birmingham Research Ethics Committee and the Birmingham and the Black Country Health Authority. Approval for use of the NHSCR for tracing was given by the Patient Information Advisory Group.
Description of Cohort
A total of 169 A-T patients from 139 separate families were included in the study. Three families each contained three siblings with A-T, and 23 families each included a pair of siblings with A-T. One pair of cousins with A-T occurred in a consanguineous family. The number of relatives per family for whom information was available ranged from two to 28 (median = 17), giving a total of 2102 blood relatives (excluding 15 stepparents of A-T patients or of their parents). We excluded 510 relatives with unknown dates of birth, 152 who were born prior to 1891, and an additional 153 relatives who could not be traced by the NHSCR. Follow-up for parents was defi ned as starting at the birth of their fi rst child with A-T, and follow-up for maternal and paternal grandparents began at the birth of the A-T patient's mother and father, respectively. Follow-up for maternal and paternal great-grandparents started 28 years before the birth of the A-T patient's mother and father respectively, to approximate the date of the relevant grandparent's birth (28 years was the average age of parents at the birth of a child with A-T in the cohort). This left-truncation of the follow-up period was performed to avoid biasing the cohort toward individuals who had, by defi nition, still been alive at the time that the A-T patient (or his or her parent or grandparent, respectively) was born. Follow-up for all other relatives began at their own dates of birth, because the A-T patient's birth was not dependent on their being alive at any particular point in time. One father was excluded because his last follow-up (when he joined the armed forces) was before the birth of his fi rst child. The cohort included a total of 1286 relatives.
For the analysis of cancer incidence, follow-up prior to 1971 was excluded because cancer registry information was not complete before then. Only fi rst cancers were considered, nonmelanoma skin cancers were excluded, and only cancers reported by the cancer registry were counted. Follow-up was assumed to cease at the earliest of July 1, 2002, the date of death, the 80th birthday, or when the individual was last reported as being alive and cancer-free. Of the 1286 relatives, 126 contributed no personyears to the cancer incidence analysis because their dates of last follow-up or death were before 1971. The proportion of relatives excluded for any of the above reasons did not differ between families with and without questionnaires ( P = 0.4).
According to the defi nitions above, the cohort for the cancer incidence analysis consisted of 1160 relatives of A-T patients from 132 families, who contributed a total of 26 220 person-years to the analysis (median = 9 relatives per family, 27.2 years per relative). The distribution between different types of relative is shown in were still alive when they exited the cohort, at a median age of 50 years (IQR = 39 to 63 years).
The follow-up period for mortality was defi ned in the same way as for cancer incidence, except that follow-up commenced on January 1, 1950. In this cohort, 644 male and 625 females contributed a total of 41 276 person-years (median = 34.2 years per relative, IQR = 22.0 to 43.7).
Genotyping
To identify the ATM mutations present in the families of A-T patients, mutation screening of the ATM gene was performed at the Cancer Research UK Institute for Cancer Studies using lymphoblastoid cell lines derived from blood samples of A-T patients. In all these A-T patients, including those for whom mutations have not yet been found, loss of ATM protein was confi rmed by Western blotting of protein extracts from the lymphoblastoid cell lines. Proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis on 6% gels and transferred electrophoretically to nitrocellulose membranes that were incubated with a monoclonal mouse -anti-human ATM antibody (11G12) ( 39 ) . Formerly, screening for ATM mutations had been carried out using restriction enzyme fi ngerprinting of PCRamplifi ed cDNA ( 22 ) . More recently, ATM mutations in A-T patients were identifi ed by denaturing high-performance liquid chromatography analysis of PCR-amplifi ed exons, followed by sequencing. For those mutations identifi ed by exon sequencing that potentially altered splicing of the RNA transcript, cDNA sequencing was also performed to confi rm sequence deletion or insertion. At least one pathogenic ATM mutation was identifi ed in 118 A-T patients from 95 families (79% of the families ascertained via the A-T Society). In eight families the A-T patients have been shown to be homozygous for different ATM mutations, and a further 40 families have been shown to carry two distinct ATM mutations. No mutation has yet been identifi ed in 12 families, and samples are not currently available for a further 30 families. Mutations were found in both parents from 33 families, in the mother but not the father in eight families, and in the father but not the mother in 10 families.
Subsequent to the initial data collection, A-T patients in two families have been shown to carry mutations in the MRE11 gene (including the consanguineous family containing a pair of cousins with A-T), rather than in ATM, and so should more properly be described as having A-T -Like Disorder (ATLD) ( 25 ) . MRE11-associated ATLD is diffi cult to distinguish clinically from A-T, although the characteristic telangiectasia features are absent in ATLD patients. These families were, however, included in the main analysis, because study entry was defi ned on the basis of a clinical, rather than a genetic, diagnosis of A-T.
Statistical Analysis
Standardized incidence ratios (SIR) were used to compare the cancer incidence in relatives with that expected in the general population. Expected numbers of cancers in each individual were based on the age, sex, and calendar-period specifi c incidence rates given for England and Wales in Cancer in Five Continents Volumes III to VIII ( 26 -31 ) using the PYEARS * N = total number of relatives in the cohort, Pyears = person-years at risk, Obs = observed cancers, Exp = expected cancers, SIR = standardized incidence ratios, CI = confi dence interval. program ( 32 ) . The 95% confi dence intervals (CIs) were derived as exact confi dence limits for a Poisson mean ( 33 ) . For the mortality analysis, mortality rates were taken from data provided by the UK Offi ce of National Statistics, and standardized mortality ratios (SMR) were computed. The parents of the A-T patients are all obligate ATM mutation carriers. No other relatives have been tested for mutations, so their carrier probabilities were estimated on the basis of their position within the pedigree, using the program MENDEL ( 34 ) , assuming that A-T is a fully penetrant recessive disorder, with mutant ATM alleles segregating according to standard Mendelian inheritance rules. The frequency of mutant alleles within the UK population was taken to be 0.3%, equivalent to approximately fi ve new A-T cases per year. The results were not sensitive to small variations in this value.
These estimated carrier probabilities ( w i , for the i th individual) were used to obtain estimates of the relative risk of cancer associated with carrying one ATM mutation, with the observed and expected numbers of cancers in each relative (O i and E i respectively) weighted by their estimated carrier probability; i.e., if the relative risk is denoted λ , then
The relative risk of cancer for the noncarriers in the cohort, φ , was computed in the same way but with the O i and E i weighted instead by the estimated probability of not carrying a mutation, 1 − w i . Estimates of λ and φ were obtained using the EM algorithm to iteratively update the individual carrier probability estimates and the relative risks ( 35 ) . Confi dence intervals were derived from the estimated covariance matrix for λ and φ ( 36 ) . For almost all individual cancer sites, there was insuffi cient information to give stable simultaneous estimates of λ and φ . Simultaneously estimating λ and φ for all sites combined gave no evidence of an overall excess of cancer incidence, cancer mortality, or non-cancer mortality in noncarrier relatives; therefore, all estimates of λ presented are those estimated under the constraint that φ = 1 (i.e., noncarrier incidence rates assumed to equal general population rates).
Relative risks were also estimated separately for carriers who were younger than 50 years of age and for those aged 50 years or older. The cutpoint of 50 years was chosen to distinguish approximately between pre-and postmenopausal breast cancers. For consistency, the same cutpoint was also used for other cancers. Cumulative risks of cancer in carriers were estimated by applying the estimated carrier relative risks (younger than 50 years of age and 50 years or older) to the population rates for England and Wales (1992 -1997) ( 29 ) .
Strictly, the relative risk estimates are not maximumlikelihood estimates because the dependence between the carrier probabilities of relatives from the same family is ignored in the iteration. However, the resulting estimates are consistent, whereas a full-likelihood analysis would theoretically require adjustment for familial aggregation of cancer, which is problematic to specify. In practice, the differences between the estimates presented here and the hypothetical full-likelihood estimates are likely to be negligible because there was rarely more than one cancer of the same type per family (i.e., no family had multiple cases of stomach or lung cancer; two families had two cases of breast cancer, and three families had two cases of colorectal cancer).
Genotype -Phenotype Correlation
Given the large number of distinct pathologic ATM mutations recorded in A-T patients (81 distinct mutations in this cohort), it is impossible to evaluate risks associated with individual mutations. Because it had been previously hypothesized that the cancer risk might be related to the residual expression of the mutant ATM protein ( 21 ) , we classifi ed mutations into three groups, according to whether any ATM protein was likely to be expressed from a mutant allele and, if so, whether the protein was likely to have kinase activity: A) frameshift mutations and substitutions leading to premature termination codons, resulting in no expression of the ATM protein from that allele; B) large (exon) or small (codon) in-frame deletions allowing some expression of a mutant ATM protein ( 37 ) that lacks kinase activity; and C) missense mutations allowing expression of mutant ATM with reduced kinase activity ( 37 ) . We have also included in this group the IVS40 -1050A>G (5672ins137) " leaky " splicing mutation that can express a low level of normal ATM protein with kinase activity ( 37 -39 ) .
The full list of observed mutations assigned to each group is given in the Supplementary Table (available at http://jncicancer spectrum.oupjournals.org/jnci/content/vol97/issue11 ). Western blotting is routinely performed on lymphoblastoid cell lines derived from A-T patients to check for loss of ATM protein as part of the confi rmation of diagnosis. The presence of some ATM protein was confi rmed in A-T cells carrying all group B and C mutations (Supplementary Table, available at http://jncicancerspectrum. oupjournals.org/jnci/content/vol97/issue11 ). If ATM protein is expressed, its kinase activity can be assayed by in vitro phosphorylation of p53 ( 39 ) or detected with phosphospecifi c antibodies to in vivo targets (e.g., p53ser15) ( 37 ) . The ATM protein associated with the 7636del9 mutation (group B) has no detectable kinase activity ( 37 ) , although the carriers of both the 7271T>G and 5672ins137 ATM mutations (group C) express ATM protein with kinase activity ( 37 , 39 ) , as do the carriers of the other three mutations in group C. Absence of detectable kinase activity was examined and confi rmed in nine patients with group B mutations (data not shown).
The pedigree analysis program MENDEL ( 34 ) was used to obtain maximum-likelihood estimates of the cancer risks associated with the three groups of mutations, assuming that all mutations must belong to one of these groups (even if there is currently insuffi cient evidence to say which). An iterative maximum-likelihood approach was necessary because of the incomplete genotype information available. This is an extension of the EM algorithm approach described earlier that allows for the nonindependence of genotypes within the same family. Along with relative risk parameters for breast cancer and all non-breast cancers in heterozygous mutation-carrying relatives, parameters for the relative risks of lymphoid tumors in A-T patients [C81 -C96 inclusive, ICD revision 10 ( 40 ) ] were included in the models. A single relative risk parameter was used to model the risk of lymphoid tumors in A-T patients with no group C mutation (i.e., no kinase activity), whereas the relative risk parameter for patients with at least one group C mutation (i.e., some kinase activity) was fi xed at 1.0. The inclusion of these parameters should improve the ability of the program to correctly predict the carrier status of untested individuals and hence give more precise relative risk estimates. In this analysis, 12 relative risk parameters were estimated for heterozygous carriers: three breast cancer relative risk parameters for women younger than 50 years of age * Obs = observed cancers, Exp = expected cancers, SIR = standardized incidence ratio, CI = confi dence interval.
(
Two families segregating the 7271T>G mutation were excluded from the genotype -phenotype analysis, because the identifi cation of these families had prompted the hypothesis that the 7271T>G missense mutation (a group C mutation) was associated with a particularly elevated breast cancer risk ( 22 ) . One further family was excluded due to uncertainty about the function of its one identifi ed mutation. The two families carrying mutations in the MRE11 gene were also excluded from this analysis (although they had been included in the main cohort analysis). This analysis was therefore based on 134 families, i.e., 268 mutant alleles. One hundred thirty-eight mutations have been identifi ed (45 families have either two known mutations or two copies of the same mutation, and 48 families have one known mutation). Of these mutations, 86 were from group A, 34 were from group B, 18 were from group C, and one was of uncertain function (3403del174). The ATM mutation frequency (0.3%) was divided among the three groups of mutations according to these proportions. Estimating the allele frequencies as parameters within the model gave essentially the same results.
To improve the statistical power, the analysis was repeated with 16 additional breast cancers that were not eligible for the main analysis, because they either occurred before 1971 or after age 80 years, or were not confi rmed by the NHSCR. Although including these cases might bias the overall relative risk estimate, there is no reason to believe that they would be biased toward any particular mutation group. Model selection was carried out using a conventional likelihood ratio test approach. All P values are two-sided; in the text, " statistically signifi cant " is used to denote a P of <.05.
R ESULTS
Overall Results for Cohort
After the exclusions described above, the cohort consisted of 1160 relatives of A-T patients from 132 families (26 220 personyears). A total of 118 fi rst cancers were reported by the NHSCR, compared with the 96.7 expected (SIR = 1.22, 95% CI = 1.02 to 1.46). Fifty-four of the cases were in men (50.3 expected), and 64 were in women (46.3 expected) (SIR = 1.07, 95% CI = 0.82 to 1.40, and SIR = 1.38, 95% CI = 1.08 to 1.77, in men and women, respectively). The median age was 50 years.
Analysis by Type of Relative
The distribution of individuals, person-years, and cancer cases among relatives of each type is shown in Table 1 . Over all types of relative, the incidence of all cancers other than breast cancer was similar to that of the general population (SIR = 1.16, 95% CI = 0.95 to 1.41). The excess was attributable largely to excess risks in aunts/uncles (SIR = 1.75, 95% CI = 1.10 to 2.64) and grandparents (SIR = 1.23, 95% CI = 0.92 to 1.63). No statistically signifi cant excess was observed in parents or greatgrandparents. The overall number of breast cancers in relatives was slightly higher than expected (SIR = 1.59, 95% CI = 1.01 to 2.38, Table 1 ). Five of the 23 eligible breast cancers were in mothers, nine in aunts, eight in grandmothers, and one in a greatgrandmother.
The 14 cancers diagnosed in parents of A-T patients are listed in Table 2 . No cancer site showed a statistically signifi cant excess. Overall, the cancer incidence in parents was similar to that predicted using general population rates.
Weighted Relative Risk Estimation
Consistent with previous observations, a statistically signifi cant excess of female breast cancer in heterozygous ATM mutation carriers was seen (RR = 2.23, 95% CI = 1.16 to 4.28, Table 3 ) compared with the general population. Excluding breast cancer, there remained some evidence of an overall increased cancer risk to ATM carriers compared with that of the general population (RR = 1.47, 95% CI = 1.00 to 2.16), which was slightly greater in female carriers (RR = 2.05, 95% CI = 1.09 to 3.84) than in male carriers (RR = 1.23, 95% CI = 0.76 to 2.00). In addition, a statistically signifi cant excess risk was observed for colorectal cancer (RR = 2.54, 95% CI = 1.06 to 6.09), and there was some suggestion of an excess of stomach cancer (RR = 3.39, 95% CI = 0.86 to 13.4). 
Age Groups
The estimated relative risks for carriers younger than 50 years of age and 50 years of age or older are summarized in Table 4 . The overall relative risk of cancer was greater for both male and female carriers younger than 50 years of age, with little evidence of an excess risk for carriers aged 50 years and older (RR = 1.04, 95% CI = 0.59 to 1.83 in males; RR = 1.64, 95% CI = 0.81 to 3.30 in females, excluding breast cancer). The estimated relative risk of breast cancer in carriers younger than 50 years of age was close to 5 (RR = 4.94, 95% CI = 1.90 to 12.9), but there was no statistically signifi cant risk for women 50 years of age and older. The overall excess cancer risk in carriers younger than 50 years of age appeared to be due to several different cancer types (for myeloma, RR = 43.3, 95% CI = 2.70 to 694; for stomach cancer, RR = 15.8, 95% CI = 1.63 to 153). One of the two buccal cavity cancers was a nasopharyngeal cancer in the 6-year-old brother of an A-T patient; this was the only juvenile cancer in a relative.
Cumulative Cancer Risks
Cumulative risks of cancer were estimated by applying the estimated relative risks for carriers to the incidence rates in the general population. The cumulative risk of breast cancer in heterozygous ATM mutation carriers was estimated to be 8.8% (95% CI = 3.5% to 21.4%) by age 50 years and 16.6% (95% CI = 9.1% to 29.3%) by age 80 years ( Fig. 1, A ) . The latter risk, that approximately one woman in six will develop breast cancer, compares with a risk of approximately one in 11 in the general population of England and Wales (1992 -1997) ( 29 ) . The estimated risk of any other cancer type by age 50 years was 5.3% (95% CI = 2.2% to 12.6%) in males and 9.0% (95% CI = 2.6% to 28.1%) in females, compared with 2.5% and 2.4%, respectively in the general population ( 29 ) . The cumulative risk of any nonbreast cancer by age 80 years was similar in male and female carriers (38.9%, 95% CI = 25.6% to 56.0%; and 35.1%, 95% CI = 20.9% to 55.0%, respectively), although the risk in females was more strongly elevated above the population risk ( Fig. 1,  B and C ) .
Based on the observed case frequency over the period 1979 -1997, we estimate the heterozygous carrier frequency to be 0.4%. Therefore, our best estimate of the fraction of breast cancer cases attributable to ATM mutations is 0.5% overall, rising to 1.6% for cases diagnosed before age 50 years.
Mortality
The overall mortality rate in males was almost identical to that expected (SMR = 1.01, 95% CI = 0.87 to 1.16). However, this rate refl ected the combination of a modestly increased risk of cancer deaths (SMR = 1.35, 95% CI = 1.07 to 1.70) with a slight, statistically non-signifi cant defi cit of non-cancer deaths (SMR = 0.88, 95% CI = 0.74 to 1.05). The relative risk of non-cancer death was similar in female relatives (SMR = 0.85, 95% CI = 0.67 to 1.09), but a higher risk of cancer deaths (SMR = 1.82, 95% CI = 1.43 to 2.32) in these relatives resulted in an overall borderline statistically signifi cantly increased mortality rate (SMR = 1.16, 95% CI = 0.98 to 1.37) as compared with the general population. The mortality in fathers was close to that expected in the general population, as was the mortality in other male relatives (data not shown). The mortality in female relatives other than mothers was also close to that expected in the general population. However, there were only two deaths in mothers (a lung cancer and a pancreatic cancer), as compared with an expected 7.90 deaths.
Seventeen deaths from breast cancer were observed in female relatives (SMR = 2.08, 95% CI = 1.21 to 3.32). Ten of these were included in the incidence analysis; the other seven were ineligible because they were reported only on death certifi cates and not by the NHSCR.
Statistically signifi cant excess cancer mortality was observed in ATM carriers of both sexes (SMR = 1.88, 95% CI = 1.14 to 3.10 and SMR = 3.56, 95% CI = 1.83 to 6.93 for males and females, respectively), whereas non-cancer mortality was slightly, but not statistically signifi cantly, lower than expected ( Table 5 ) . There was no evidence of excess mortality from either vascular or respiratory disease. Statistically signifi cant excesses in mortality in ATM carriers were estimated for breast cancer (RR = 4.18, 95% CI = 1.38 to 12.7), stomach cancer (RR = 4.19, 95% CI = 1.49 to 11.8), colorectal cancer (RR = 3.19, 95% CI = 1.24 to 8.23), and lung cancer (RR = 2.36, 95% CI = 1.24 to 4.50) as compared with the general population.
ATM carrier relative risks were also estimated separately for deaths before or after age 50 years ( Table 6 ). The estimated cancer * The cancer sites shown are those for which either the overall carrier RR was statistically signifi cantly greater than 1 or for which there were 10 or more cases. In addition, there were two or more cases in the younger age group of buccal cavity and pharynx cancer (two cases), uterus cancer (two cases), and myeloma (two cases). Obs = observed cancers, Exp = expected cancers. particularly elevated in ATM carriers below age 50 years (stomach cancer, RR = 14.0, 95% CI = 3.18 to 61.9; and colorectal cancer, RR = 11.0, 95% CI = 2.55 to 47.2).
Genotype -Phenotype Correlations
Risks of breast and non-breast cancers in relatives were estimated for the three categories of ATM mutation. There were no statistically signifi cant differences between the mutation groups in the risks of either non-breast cancer ( P = .5) or breast cancer ( P = .8). When 16 additional breast cancer cases were included, the risk was highest for patients with mutations expressing some protein without kinase activity (group B) (comparing groups B and A, RR = 2.5, 95% CI = 0.7 to 8.9) and slightly lower for those with mutations retaining kinase activity (group C) (comparing groups C and A, RR = 0.9, 95% CI = 0.1 to 8.9), although the differences were not statistically signifi cant ( P = .4).
D ISCUSSION
We have studied the cancer incidence and the mortality in 1160 blood relatives of A-T patients from 132 families and have found evidence for an increased risk of breast cancer in heterozygous ATM mutation carriers, chiefl y at young ages, accompanied by a more moderate increase in the risk of other cancers. The overall estimated breast cancer relative risk to heterozygous ATM carriers was 2.23 (95% CI = 1.16 to 4.28 ) , with a relative risk of 4.94 (95% CI = 1.90 to 12.9) in carriers younger than 50 years of age. This is equivalent to a lifetime (until age 80 years) risk of approximately one woman in six, as compared with one in 11 in the general population of England and Wales. * Obs = observed cancers, Exp = expected cancers, ICD = International Classification of Disease.
† The " other " cancers were three female genital cancers and a cancer of the middle ear. mortality relative risks were higher for carriers younger than 50 years of age than for carriers aged 50 years and older (RR = 3.59, 95% CI = 1.74 to 7.38; and RR = 2.23, 95% CI = 1.44 to 3.45, respectively). Consistent with the incidence analysis, the relative risk of breast cancer mortality was higher for carriers below age 50 years (RR = 6.08, 95% CI = 1.05 to 35.3) than for carriers aged 50 years and older (RR = 3.45, 95% CI = 0.89 to 13.4). Mortality from stomach cancer and colorectal cancer was also Cumulative risks of cancer in heterozygous ATM mutation carriers, estimated from cancer incidence in 1160 relatives of A-T patients from 132 UK families. A ) Estimated cumulative risks of breast cancer in female heterozygous ATM mutation carriers. B ) Estimated cumulative risks of all cancers in male heterozygous ATM mutation carriers. C ) Estimated cumulative risks of all cancers other than breast cancer in female heterozygous ATM mutation carriers. Estimated cumulative risks to carriers along with 95% confi dence intervals ( solid lines ) and cumulative risks in the general population [England and Wales, 1992 -1997 ( 29 ) hatched lines ] are shown, at each 10-year age point. Cumulative risks were obtained by applying the estimated RRs to carriers below and above age 50 (estimated using the EM algorithm) to the general population rates.
The estimated risk of any cancer in male carriers by the age of 80 years was only slightly higher than in the general population (39% vs. 36%), whereas the risk by age of 80 years of any cancer other than breast cancer in female carriers was considerably higher than in the general population (35% vs. 21%).
Although there was little evidence for an overall excess risk of cancers other than breast cancer in ATM heterozygotes, there was some evidence for excess risks of colorectal cancer and stomach cancer. We also observed a clear excess mortality from cancer, with statistically signifi cant excess risks of stomach, colorectal, and lung cancer deaths. The higher relative risks based on mortality might refl ect some underreporting of cancers by the NHSCR but could also refl ect a more aggressive behavior of cancers in ATM carriers. Two previous studies have hinted at a possible association between ATM and cancers of the gastrointestinal tract, although neither association was statistically signifi cant ( 7 , 9 ) . In contrast to our study, neither study found any evidence of a specifi c excess of colorectal cancers in relatives of A-T patients.
Some limitations of this study that may lead to biased relative risk estimates include incomplete ascertainment of families, possible nonpaternity or de novo ATM mutations, and the possibility that some A-T patients may not carry ATM mutations. A further limitation is that we were able to genotype only the parents of A-T patients and not any other relatives. Although this reduced the power of the study and the precision of the relative risk estimates, it should not result in any bias, providing that ATM mutations are inherited according to Mendelian rules. The precision of the estimates was also limited by the number of available A-T families. Further precision should, however, be obtained through combined analysis of our data with those from other European studies.
We have attempted to minimize bias in this study by systematically following a defi ned cohort of relatives of all known A-T patients and by basing analysis only on registered cancers and deaths reported through national records, to allow direct comparability of observed and expected rates. Nevertheless, some potential biases remain. First, families in which a parent died at a young age might be less likely to have participated in the study. We attempted to minimize this bias by including additional families ascertained through a mention of A-T on a death certifi cate. That some bias remains is borne out by a marked defi cit in mortality in mothers, with two deaths observed, compared with nearly eight expected. This bias is refl ected in the slight defi cit in overall mortality from nonmalignant causes and suggests that the excess mortality from and incidence of cancer may therefore have been underestimated.
Other events that would reduce the number of mutations in relatives, and hence underestimate the risks, are nonpaternity and de novo mutations. One A-T patient in the cohort is known to carry an inherited truncating mutation alongside a de novo paternal missense mutation, 8189A>C. This is generally considered to be a very rare event in A-T. There was no evidence of incompatible paternal genotypes among the genotyped parents of the A-T patients. Although there may be instances of false paternity among grandparents or great-grandparents, any such events would not affect the carrier probabilities of as many family members.
Strictly speaking, the estimates are a weighted average of the risks conferred by ATM and MRE11 mutations. The apparent A-T cases in two of the families are in fact due to compound heterozygous mutations in the MRE11 gene. The relative sizes of the two genes would suggest that approximately 6% of A-T patients might in fact carry MRE11 mutations, i.e., approximately six further families ( 25 ) . MRE11 acts in the same DNA damage response pathway as does ATM, but mutations in the two genes need not predispose to cancer to the same extent; there is no evidence that homozygous Mre11 mutations are associated with tumors in mice ( 41 ) . If MRE11 mutations conferred no excess cancer risk, then the ATM excess cancer risk estimated in this study could be underestimated by approximately 6%.
In addition to the excesses of breast, colorectal, and stomach cancer noted above, a statistically signifi cant excess of cancer of the gallbladder was also observed, but this was based on only three cases. A high relative risk was estimated for " other female genital cancers, " but this was based on just two cases and was not statistically signifi cant. Three further female genital cancers were also reported but did not contribute to the analysis. A high relative risk (RR = 4.5) was also estimated for myeloma, based on three cases. It is noteworthy that these were the only lymphoid tumors seen in relatives and that no myelomas were observed in A-T patients.
The apparent excesses at some or all of these sites could be due to chance, given the number of cancer sites evaluated, and larger studies will be required to determine whether these effects are genuine. Conversely, moderate risks of other cancers in ATM carriers cannot be ruled out. The modest overall increase in the risk of non-breast cancer appears to be due largely to a combination of small increases at many sites; it is notable that all the relative risk estimates in Table 3 are greater than 1, with the exception of brain cancer and cancers of unknown site. Our study is comparable in design to two recent European studies, one based in France ( 42 ) and the other in the Nordic countries ( 9 ) . The Nordic study obtained cancer incidence data for 1218 relatives of A-T patients from 50 families via record linkage to national cancer registries. Its authors estimated the breast cancer relative risk for ATM carriers to be 2.4 (95% CI = 1.3 to 4.1), which is very similar to our estimate. Breast cancer was the only individual cancer with a statistically signifi cant excess; apart from breast cancer, they observed only 15% more cancers than expected in relatives of A-T patients.
The French study was based on 1423 relatives of A-T patients from 34 families. ATM genotyping was performed on over a quarter of the relatives, but not all cancer cases had been formally confi rmed. The relative risk of breast cancer, weighted by prior carrier probability (RR = 2.43, 95% CI = 1.32 to 4.09) was also very similar to our estimate (RR = 2.23, 95% CI = 1.16 to 4.28). In the French study, the relative risk was higher for women below age 45 years, but no excess was seen in women above this age (RR = 6.32, 95% CI =1.94 to 15.2, and RR = 0.68, 95% CI = 0.08 to 2.46, respectively). There was no evidence of an increased risk of cancers other than breast cancers in carriers in this study ( 42 ) .
The results presented here are generally in line with the French and Nordic studies. Our study has the advantage of being based on a far larger number of families, and, although the number of eligible relatives in our cohort was slightly smaller, the exclusion of cousins and great-aunts/uncles meant that the cohort had a higher density of mutation carriers. Previous studies have either presented separate relative risks for each type of relative, often with large confi dence intervals as a consequence of the small numbers of cases in each group, or have pooled all relatives into a single group, without taking into account their different carrier probabilities. In contrast, our use of the EM algorithm to obtain maximum-likelihood estimates of the carrier relative risks, based on weighting the information from all relatives, made more efficient use of the data. In common with the Nordic study (but not the French study), we considered only cancer cases that had been formally confi rmed. Neither of the other European studies considered both cancer incidence and mortality.
We found no evidence for any difference in risk of breast or other cancer according to the type of ATM mutation. If anything, the trend was toward a lower breast cancer risk for the group C mutations, in contrast with previous reports that showed that missense mutations, in particular 7271T>G, are associated with a markedly increased risk of breast cancer ( 19 -22 ) . Our estimates were necessarily imprecise, because group C mutations were the least frequent in this set; after the exclusion of the two hypothesis-generating 7271T>G families ( 22 ) , there was only one breast cancer in a family branch known to carry a group C mutation. Furthermore, because the 5762ins137 mutation accounted for 14 out of 18 of the known group C family branches, the results may not be generalizable to all ATM mutations retaining kinase activity.
The mutation categories were devised in the context of A-T patients with two germline mutations in trans , whereas the analysis of cancer risks was restricted to heterozygous carriers, in whom these particular differences between mutations may be less important. For a single mutation in the presence of a wild-type allele, alternative mechanisms may become relevant to the disease process, potentially including haploinsuffi ciency (group A), dominant-negative effects (groups B and C), or some gain in function (groups B and C). For example, lymphoblastoid cell lines with a heterozygous missense mutation have been shown to have higher ATM mRNA expression than do cell lines with a truncating mutation and to have poorer cell survival following irradiation ( 43 ) .
A recent study of 34 French A-T families found no difference between the breast cancer risks associated with heterozygous truncating and missense/in-frame deletion ATM mutations but identifi ed three groups of truncating mutations with particularly high breast cancer relative risks, each relating to a known binding domain ( 42 ) . However, we observed no breast cancers in the seven family branches with mutations that truncate the ATM protein in these domains.
It is important to note that our results do not exclude the possibility of more substantial heterogeneity at the mutation level. Despite all these uncertainties, the results do appear to confi rm that a substantial risk of breast cancer is conferred by mutations that eliminate the ATM protein and that the risk is not restricted to a subset of missense mutations.
The breast cancer risk we have estimated would be suffi cient to classify an ATM carrier as " moderate risk, " according to recent guidelines of the National Institute for Clinical Excellence (2004). These guidelines suggest that annual mammography beginning at age 40 years may be appropriate in this risk group. However, given the role of ATM in radiation-induced DNA repair, it is not clear whether mammographic screening would be benefi cial in ATM carriers. Recent studies have suggested that magnetic resonance imaging may be a sensitive screening tool in women at high risk of breast cancer, such as BRCA1 and BRCA2 carriers ( 44 ) , and it may provide an alternative management approach for ATM carriers. Further research would be needed to evaluate the appropriateness of any specifi c screening for gastric, colorectal, or other cancers.
In conclusion, this study has confi rmed an approximately twofold-increased risk of breast cancer in female carriers of ATM mutations, with a higher relative risk for those younger than 50 years. We also identifi ed increased risk of colorectal cancer and a possible increased risk of stomach cancer. Combined analyses with similar cohorts and further follow-up will be required to provide reliable risk estimates for other cancer sites and to investigate mutation-specifi c effects.
